EGFR and non-small cell lung carcinoma: We hope that this specific case provide valuable insights into the management of patients with <i>EGFR</i> mutation-associated NSCLC with LM.<h4>Conclusion</h4>Furmonertinib, a third-generation <i>EGFR</i> TKI with notable BBB penetration, shows promise in LM control and the rapid alleviation of intracranial symptoms.